Thursday, October 24, 2013

NEJM study exposes overuse of radiation therapy when urologists profit from self-referral

NEJM study exposes overuse of radiation therapy when urologists profit from self-referral


[ Back to EurekAlert! ]

PUBLIC RELEASE DATE:

23-Oct-2013



[


| E-mail

]


Share Share

Contact: Michelle Kirkwood
michellek@astro.org
703-286-1600
American Society for Radiation Oncology



IMRT use is 2 1/2 times greater when self-referral's financial incentives are involved



Fairfax, Va., October 23, 2013A comprehensive review of Medicare claims for more than 45,000 patients from 2005 through 2010 found that nearly all of the 146 percent increase in intensity-modulated radiation therapy (IMRT) for prostate cancer among urologists with an ownership interest in the treatment was due to self-referral, according to new research, "Urologists' Use of Intensity-Modulated Radiation Therapy for Prostate Cancer," released today in The New England Journal of Medicine (NEJM) for its October 24, 2013 issue. This study corroborates the increased IMRT treatment rates among self-referrers reported in the Government Accountability Office's (GAO) August 2013 report, "Medicare: Higher Use of Costly Prostate Cancer Treatment by Providers Who Self-Refer Warrants Scrutiny."


Authored by Jean M. Mitchell, PhD, economist and professor at the McCourt School of Public Policy at Georgetown University, the NEJM manuscript provides an intricate analysis of treatment patterns by urologists before and after they acquired ownership of IMRT services, compared to the treatment patterns of non-self-referring urologists and urologists who practice at National Comprehensive Cancer Network (NCCN)-designated cancer centers (also non-self-referrers).


ASTRO Chairman Colleen A.F. Lawton, MD, FASTRO, voiced the Society's grave concerns regarding this study's results, "Dr. Mitchell's study provides clear, indisputable evidence that many men are receiving unnecessary radiation therapy for their prostate cancer due to self-referral. While I am a prostate cancer specialist impassioned to eradicating the disease, I am equally dedicated to utilizing these powerful technologies prudently and in the best interest of each individual patient. We must end physician self-referral for radiation therapy and protect patients from this type of abuse."


The two cohorts for the NEJM study data, obtained through Medicare claims from January 1, 2005 through December 31, 2010, include Medicare patients in 26 geographically dispersed states who were 1) treated at 35 self-referring urology groups in private practice matched to a control group of 35 non-self-referring urology groups in private practice, for a total of 38,765 patients; and 2) treated by 11 self-referring urology groups in private practice within close proximity to and matched directly to non-self-referring urologists at 11 NCCN centers, for a total of 6,713 patients. Patient records were followed for a period of six months from the initial prostate cancer diagnosis to track treatment choices. Sixty percent of the self-referring urologists established their IMRT services during the period from January 1, 2008 through January 15, 2010.


A difference-in-differences analysis was used to isolate the impact of self-referral on changes of IMRT utilization over time, according to self-referral status. This approach controls for initial differences in practice patterns during the pre-ownership period as well as secular trends that affect the use of IMRT and are unrelated to ownership status. The analysis found that:

  • IMRT utilization among self-referring groups increased from 13.1 percent to 32.3 percent once they became self-referrers, an increase of 19.2 percentage points (146 percent). In contrast, IMRT utilization by non-self-referring urologists who were peers practicing in the same community-based setting was virtually unchangedwith a modest increase of 1.3 percentage points. Therefore, the difference-in-differences analysis reveals that self-referral accounts for 93 percent of the growth in IMRT.
  • IMRT utilization among the subset of 11 self-referring urology practices near NCCN centers increased from 9 percent to 42 percent, an increase of 33 percentage points (367 percent), from the pre-ownership to the ownership period, compared to an insignificant increase of 0.4 percentage points at the NCCN centers.
  • In addition to increased IMRT utilization, the data demonstrate decreases in utilization of other effective, less expensive treatment options by self-referring urologists. For example, brachytherapy decreased by 14.9 percentage points to just 2.7 percent of patients receiving this treatment in self-referring urology practices. These results are in stark contrast to non-self-referring urologists, for whom the study reports "virtually no change in practice patterns."

The NEJM report concludes that "men treated by self-referring urologists, as compared with men treated by non-self-referring urologists, are much more likely to undergo IMRT, a treatment with a high reimbursement rate, rather than less expensive options, despite evidence that all treatments yield similar outcomes."


At a press conference unveiling the study tomorrow, one of the nation's leading urologists, James L. Mohler, MD, of Roswell Park Cancer Institute in Buffalo, will release a joint statement on the overtreatment of prostate cancer and physician self-referral from the expert members of the NCCN Prostate Cancer Guidelines Panel, which he chairs.


"We are concerned unanimously by the prostate cancer treatment patterns identified in today's article," says Dr. Mohler. "We are disappointed to learn that urologists who self-refer for IMRT services use this expensive technology more than urologists who don't self-refer and more than NCCN Member Institutions." He added, "Prostate cancer treatment recommendations should be based on the best available clinical evidence and not influenced by business or personal interests of the care provider."


"This study confirms that permitting physicians to self-refer, particularly urologists to self-refer for IMRT, leads to unnecessary treatment and added health care costs to Medicare and beneficiaries," continued Dr. Lawton. "Prostate cancer is a complicated disease that needs input from multiple specialists, not just one, to determine the best treatment for the individual patient. There are many different treatments available, and in many cases, no treatment at all is the right thing to do, particularly among the elderly. For many men with early stage prostate cancer, active surveillance, or watchful waiting, is the best option. Unfortunately, the continuous stream of data indicates that patient choice is being restrictedpatients are being steered to the treatment that provides the most profit for the urologist. As a result, patients are subjected to unnecessary treatment and side effects, and millions of dollars are wasted."


The federal "Ethics in Patient Referrals Act," also known as the self-referral law, prohibits physicians from referring a patient to a medical facility in which he or she has a financial interest in order to ensure that medical decisions are made in the best interest of the patient without consideration of any financial gain that could be realized by the treating physician. However, the law includes an exception that allows physicians to self-refer for so-called "ancillary services," including radiation therapy. Over the years, abuse of the in-office ancillary services (IOAS) exception has weakened the self-referral law and diminished its policy objectives, making it simple for physicians to avoid the law's prohibitions by structuring arrangements that meet the technical requirements of the law, thereby circumventing the intent of the law. Numerous studies have shown that physician self-referral leads to increased utilization of services that may not be medically necessary, poses a potential risk of harm to patients and costs the health care system millions of dollars each year.


To-date, the GAO has issued three reports in a four-part series on physician self-referral, the most recent one, from August 2013, also details abuse in radiation therapy treatment for prostate cancer. The report found a 356 percent increase in IMRT utilization by self-referrers, compared to a 5 percent decrease by non-self-referrers, and that the number of treatments rose by 509 percent compared to a 3.8 percent decrease at non-self-referring multi-specialty groups. In July 2013, the GAO report, "Action Needed to Address Higher Use of Anatomic Pathology Services by Providers Who Self-Refer," found that self-referring providers likely referred nearly one million more unnecessary anatomic pathology services than non-self-referring providers, costing Medicare approximately $69 million. "Higher Use of Advanced Imaging Services by Providers Who Self-Refer Costing Medicare Millions," the first GAO report in November 2012 on self-referral in advanced diagnostic imaging, found that "providers who self-referred likely made 400,000 more referrals for advanced imaging services than they would have if they were not self-referring"at a cost of more than $100 million in 2010. The final report, expected by the end of this year, will detail self-referral for physical therapy services.


"Unfortunately, when you look at the numbers in this report, you start to wonder where health care stops and where profiteering begins," said Senate Finance Committee Chairman Max Baucus (D-Mont.), in a statement about the GAO's August 2013 report on radiation therapy self-referral. "Enough is enough. Congress needs to close this loophole and fix the problem."


"ASTRO urges Congress to promptly pass the 'Promoting Integrity in Medicare Act of 2013' (PIMA), introduced August 1, 2013, by Rep. Jackie Speier (D-Calif.) and Rep. Jim McDermott (D-Wash.). PIMA will close the self-referral loophole for radiation therapy, advanced imaging, anatomic pathology and physical therapy services, resulting in better care for patients and billions of Medicare dollars saved that could offset the costs of repealing the Medicare physician payment formula (sustainable growth rateSGR).


"PIMA closes the self-referral loophole in a conscientious and strategic manner that abolishes abuse while allowing truly integrated multi-specialty groups and high-performing health systems to continue to provide high-quality and efficient care," concluded Dr. Lawton. "This blatant abuse of our patient's trust and our country's limited financial resources endangers our ability to work with health policy leaders in developing a new quality- and value-based payment system for Medicare. Closing the self-referral loophole will protect patients, restore trust, reduce costs and strengthen Medicare."


Reps. Speier's and McDermott's PIMA legislation would enact the recommendations of influential bipartisan groups who have examined self-referral abuse. In September 2012, a New England Journal of Medicine article, authored by leading health policy experts including former CMS administrator Donald Berwick, MD, MPP, called for closing the self-referral loophole for radiation therapy and other so-called "ancillary services." The Center for American Progress agreed with narrowing the IOAS exception, as well as several notable bipartisan groups, including the Bipartisan Policy Center, under the leadership of former Senate Majority Leaders Tom Daschle (D-S.D.) and Bill Frist (R-Tenn.), and the Moment of Truth Project, headed by Erskine Bowles and former Senator Alan Simpson (R-Wyo.). President Obama's proposed FY 2014 Budget also recommended closing the self-referral loophole and estimated savings of more than $6 billion during the standard 10-year budget window for Medicare.


A November 2012 Bloomberg News investigative report scrutinized questionable IMRT treatment for prostate cancer by a self-referring urology clinic in California and concluded that physician self-referral resulted in mistreated patients and higher health care costs. The Wall Street Journal, The Washington Post and The Baltimore Sun have published similarly critical reports since 2009 to call attention to the mounting evidence that limited specialty [urology] groups who own radiation therapy equipment have utilization rates that rise rapidly and are well above the national norms for radiation treatment of prostate cancer.


###


The NEJM study was approved by the institutional review board of Georgetown University and funded by an unrestricted educational research contract between ASTRO and Georgetown University. No potential conflict of interest relevant to the study is reported.


ABOUT ASTRO

ASTRO is the premier radiation oncology society in the world, with more than 10,000 members who are physicians, nurses, biologists, physicists, radiation therapists, dosimetrists and other health care professionals that specialize in treating patients with radiation therapies. As the leading organization in radiation oncology, the Society is dedicated to improving patient care through professional education and training, support for clinical practice and health policy standards, advancement of science and research, and advocacy. ASTRO publishes two medical journals, International Journal of Radiation Oncology Biology Physics and Practical Radiation Oncology; developed and maintains an extensive patient website, http://www.rtanswers.org; and created the Radiation Oncology Institute, a non-profit foundation to support research and education efforts around the world that enhance and confirm the critical role of radiation therapy in improving cancer treatment. To learn more about ASTRO, visit http://www.astro.org.


[ Back to EurekAlert! ]

[


| E-mail


Share Share

]

 


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.




NEJM study exposes overuse of radiation therapy when urologists profit from self-referral


[ Back to EurekAlert! ]

PUBLIC RELEASE DATE:

23-Oct-2013



[


| E-mail

]


Share Share

Contact: Michelle Kirkwood
michellek@astro.org
703-286-1600
American Society for Radiation Oncology



IMRT use is 2 1/2 times greater when self-referral's financial incentives are involved



Fairfax, Va., October 23, 2013A comprehensive review of Medicare claims for more than 45,000 patients from 2005 through 2010 found that nearly all of the 146 percent increase in intensity-modulated radiation therapy (IMRT) for prostate cancer among urologists with an ownership interest in the treatment was due to self-referral, according to new research, "Urologists' Use of Intensity-Modulated Radiation Therapy for Prostate Cancer," released today in The New England Journal of Medicine (NEJM) for its October 24, 2013 issue. This study corroborates the increased IMRT treatment rates among self-referrers reported in the Government Accountability Office's (GAO) August 2013 report, "Medicare: Higher Use of Costly Prostate Cancer Treatment by Providers Who Self-Refer Warrants Scrutiny."


Authored by Jean M. Mitchell, PhD, economist and professor at the McCourt School of Public Policy at Georgetown University, the NEJM manuscript provides an intricate analysis of treatment patterns by urologists before and after they acquired ownership of IMRT services, compared to the treatment patterns of non-self-referring urologists and urologists who practice at National Comprehensive Cancer Network (NCCN)-designated cancer centers (also non-self-referrers).


ASTRO Chairman Colleen A.F. Lawton, MD, FASTRO, voiced the Society's grave concerns regarding this study's results, "Dr. Mitchell's study provides clear, indisputable evidence that many men are receiving unnecessary radiation therapy for their prostate cancer due to self-referral. While I am a prostate cancer specialist impassioned to eradicating the disease, I am equally dedicated to utilizing these powerful technologies prudently and in the best interest of each individual patient. We must end physician self-referral for radiation therapy and protect patients from this type of abuse."


The two cohorts for the NEJM study data, obtained through Medicare claims from January 1, 2005 through December 31, 2010, include Medicare patients in 26 geographically dispersed states who were 1) treated at 35 self-referring urology groups in private practice matched to a control group of 35 non-self-referring urology groups in private practice, for a total of 38,765 patients; and 2) treated by 11 self-referring urology groups in private practice within close proximity to and matched directly to non-self-referring urologists at 11 NCCN centers, for a total of 6,713 patients. Patient records were followed for a period of six months from the initial prostate cancer diagnosis to track treatment choices. Sixty percent of the self-referring urologists established their IMRT services during the period from January 1, 2008 through January 15, 2010.


A difference-in-differences analysis was used to isolate the impact of self-referral on changes of IMRT utilization over time, according to self-referral status. This approach controls for initial differences in practice patterns during the pre-ownership period as well as secular trends that affect the use of IMRT and are unrelated to ownership status. The analysis found that:

  • IMRT utilization among self-referring groups increased from 13.1 percent to 32.3 percent once they became self-referrers, an increase of 19.2 percentage points (146 percent). In contrast, IMRT utilization by non-self-referring urologists who were peers practicing in the same community-based setting was virtually unchangedwith a modest increase of 1.3 percentage points. Therefore, the difference-in-differences analysis reveals that self-referral accounts for 93 percent of the growth in IMRT.
  • IMRT utilization among the subset of 11 self-referring urology practices near NCCN centers increased from 9 percent to 42 percent, an increase of 33 percentage points (367 percent), from the pre-ownership to the ownership period, compared to an insignificant increase of 0.4 percentage points at the NCCN centers.
  • In addition to increased IMRT utilization, the data demonstrate decreases in utilization of other effective, less expensive treatment options by self-referring urologists. For example, brachytherapy decreased by 14.9 percentage points to just 2.7 percent of patients receiving this treatment in self-referring urology practices. These results are in stark contrast to non-self-referring urologists, for whom the study reports "virtually no change in practice patterns."

The NEJM report concludes that "men treated by self-referring urologists, as compared with men treated by non-self-referring urologists, are much more likely to undergo IMRT, a treatment with a high reimbursement rate, rather than less expensive options, despite evidence that all treatments yield similar outcomes."


At a press conference unveiling the study tomorrow, one of the nation's leading urologists, James L. Mohler, MD, of Roswell Park Cancer Institute in Buffalo, will release a joint statement on the overtreatment of prostate cancer and physician self-referral from the expert members of the NCCN Prostate Cancer Guidelines Panel, which he chairs.


"We are concerned unanimously by the prostate cancer treatment patterns identified in today's article," says Dr. Mohler. "We are disappointed to learn that urologists who self-refer for IMRT services use this expensive technology more than urologists who don't self-refer and more than NCCN Member Institutions." He added, "Prostate cancer treatment recommendations should be based on the best available clinical evidence and not influenced by business or personal interests of the care provider."


"This study confirms that permitting physicians to self-refer, particularly urologists to self-refer for IMRT, leads to unnecessary treatment and added health care costs to Medicare and beneficiaries," continued Dr. Lawton. "Prostate cancer is a complicated disease that needs input from multiple specialists, not just one, to determine the best treatment for the individual patient. There are many different treatments available, and in many cases, no treatment at all is the right thing to do, particularly among the elderly. For many men with early stage prostate cancer, active surveillance, or watchful waiting, is the best option. Unfortunately, the continuous stream of data indicates that patient choice is being restrictedpatients are being steered to the treatment that provides the most profit for the urologist. As a result, patients are subjected to unnecessary treatment and side effects, and millions of dollars are wasted."


The federal "Ethics in Patient Referrals Act," also known as the self-referral law, prohibits physicians from referring a patient to a medical facility in which he or she has a financial interest in order to ensure that medical decisions are made in the best interest of the patient without consideration of any financial gain that could be realized by the treating physician. However, the law includes an exception that allows physicians to self-refer for so-called "ancillary services," including radiation therapy. Over the years, abuse of the in-office ancillary services (IOAS) exception has weakened the self-referral law and diminished its policy objectives, making it simple for physicians to avoid the law's prohibitions by structuring arrangements that meet the technical requirements of the law, thereby circumventing the intent of the law. Numerous studies have shown that physician self-referral leads to increased utilization of services that may not be medically necessary, poses a potential risk of harm to patients and costs the health care system millions of dollars each year.


To-date, the GAO has issued three reports in a four-part series on physician self-referral, the most recent one, from August 2013, also details abuse in radiation therapy treatment for prostate cancer. The report found a 356 percent increase in IMRT utilization by self-referrers, compared to a 5 percent decrease by non-self-referrers, and that the number of treatments rose by 509 percent compared to a 3.8 percent decrease at non-self-referring multi-specialty groups. In July 2013, the GAO report, "Action Needed to Address Higher Use of Anatomic Pathology Services by Providers Who Self-Refer," found that self-referring providers likely referred nearly one million more unnecessary anatomic pathology services than non-self-referring providers, costing Medicare approximately $69 million. "Higher Use of Advanced Imaging Services by Providers Who Self-Refer Costing Medicare Millions," the first GAO report in November 2012 on self-referral in advanced diagnostic imaging, found that "providers who self-referred likely made 400,000 more referrals for advanced imaging services than they would have if they were not self-referring"at a cost of more than $100 million in 2010. The final report, expected by the end of this year, will detail self-referral for physical therapy services.


"Unfortunately, when you look at the numbers in this report, you start to wonder where health care stops and where profiteering begins," said Senate Finance Committee Chairman Max Baucus (D-Mont.), in a statement about the GAO's August 2013 report on radiation therapy self-referral. "Enough is enough. Congress needs to close this loophole and fix the problem."


"ASTRO urges Congress to promptly pass the 'Promoting Integrity in Medicare Act of 2013' (PIMA), introduced August 1, 2013, by Rep. Jackie Speier (D-Calif.) and Rep. Jim McDermott (D-Wash.). PIMA will close the self-referral loophole for radiation therapy, advanced imaging, anatomic pathology and physical therapy services, resulting in better care for patients and billions of Medicare dollars saved that could offset the costs of repealing the Medicare physician payment formula (sustainable growth rateSGR).


"PIMA closes the self-referral loophole in a conscientious and strategic manner that abolishes abuse while allowing truly integrated multi-specialty groups and high-performing health systems to continue to provide high-quality and efficient care," concluded Dr. Lawton. "This blatant abuse of our patient's trust and our country's limited financial resources endangers our ability to work with health policy leaders in developing a new quality- and value-based payment system for Medicare. Closing the self-referral loophole will protect patients, restore trust, reduce costs and strengthen Medicare."


Reps. Speier's and McDermott's PIMA legislation would enact the recommendations of influential bipartisan groups who have examined self-referral abuse. In September 2012, a New England Journal of Medicine article, authored by leading health policy experts including former CMS administrator Donald Berwick, MD, MPP, called for closing the self-referral loophole for radiation therapy and other so-called "ancillary services." The Center for American Progress agreed with narrowing the IOAS exception, as well as several notable bipartisan groups, including the Bipartisan Policy Center, under the leadership of former Senate Majority Leaders Tom Daschle (D-S.D.) and Bill Frist (R-Tenn.), and the Moment of Truth Project, headed by Erskine Bowles and former Senator Alan Simpson (R-Wyo.). President Obama's proposed FY 2014 Budget also recommended closing the self-referral loophole and estimated savings of more than $6 billion during the standard 10-year budget window for Medicare.


A November 2012 Bloomberg News investigative report scrutinized questionable IMRT treatment for prostate cancer by a self-referring urology clinic in California and concluded that physician self-referral resulted in mistreated patients and higher health care costs. The Wall Street Journal, The Washington Post and The Baltimore Sun have published similarly critical reports since 2009 to call attention to the mounting evidence that limited specialty [urology] groups who own radiation therapy equipment have utilization rates that rise rapidly and are well above the national norms for radiation treatment of prostate cancer.


###


The NEJM study was approved by the institutional review board of Georgetown University and funded by an unrestricted educational research contract between ASTRO and Georgetown University. No potential conflict of interest relevant to the study is reported.


ABOUT ASTRO

ASTRO is the premier radiation oncology society in the world, with more than 10,000 members who are physicians, nurses, biologists, physicists, radiation therapists, dosimetrists and other health care professionals that specialize in treating patients with radiation therapies. As the leading organization in radiation oncology, the Society is dedicated to improving patient care through professional education and training, support for clinical practice and health policy standards, advancement of science and research, and advocacy. ASTRO publishes two medical journals, International Journal of Radiation Oncology Biology Physics and Practical Radiation Oncology; developed and maintains an extensive patient website, http://www.rtanswers.org; and created the Radiation Oncology Institute, a non-profit foundation to support research and education efforts around the world that enhance and confirm the critical role of radiation therapy in improving cancer treatment. To learn more about ASTRO, visit http://www.astro.org.


[ Back to EurekAlert! ]

[


| E-mail


Share Share

]

 


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.




Source: http://www.eurekalert.org/pub_releases/2013-10/asfr-nse102313.php
Tags: randall cobb   Dallas Latos   Cassidy Wolf   michael beasley   monday night football  

Kristen Bell’s First Post-Wedding Outing!

She got hitched to Dax Shepard last week, and Kristen Bell looked like a blissful newlywed while out in Los Angeles on Sunday (October 20).


The “Veronica Mars” starlet donned a fedora as she headed over to a friend’s house carrying a water bottle and a change of clothes.


Over the summer, Kristen rejoiced at the Supreme Court’s defeat of the Defense of Marriage Act and ended up proposing to Dax as a result.


Prior to the decision, she told press, "The reason we're not rushing to get married is because I don't feel appropriate taking advantage of a right that's denied to my [gay and lesbian] friends.”


Source: http://celebrity-gossip.net/kristen-bell/kristen-bell%E2%80%99s-first-post-wedding-outing-1043254
Related Topics: apple   jay cutler   notre dame   Eminem Survival   Snowden  

Predicting the fate of stem cells

Predicting the fate of stem cells


[ Back to EurekAlert! ]

PUBLIC RELEASE DATE:

22-Oct-2013



[


| E-mail

]


Share Share

Contact: Erin Vollick
Comm.ibbme@utoronto.ca
416-946-8019
University of Toronto



Technique has potential use in regenerative medicine and drug development



University of Toronto researchers have developed a method that can rapidly screen human stem cells and better control what they will turn into. The technology could have potential use in regenerative medicine and drug development. Findings are published in this week's issue of the journal Nature Methods.


"The work allows for a better understanding of how to turn stem cells into clinically useful cell types more efficiently," according to Emanuel Nazareth, a PhD student at the Institute of Biomaterials & Biomedical Engineering (IBBME) at the University of Toronto. The research comes out of the lab of Professor Peter Zandstra, Canada Research Chair in Bioengineering at U of T.


The researchers used human pluripotent stem cells (hPSC), cells which have the potential to differentiate and eventually become any type of cell in the body. But the key to getting stem cells to grow into specific types of cells, such as skin cells or heart tissue, is to grow them in the right environment in culture, and there have been challenges in getting those environments (which vary for different types of stem cells) just right, Nazareth said.


The researchers developed a high-throughput platform, which uses robotics and automation to test many compounds or drugs at once, with controllable environments to screen hPSCs in. With it, they can control the size of the stem cell colony, the density of cells, and other parameters in order to better study characteristics of the cells as they differentiate or turn into other cell types. Studies were done using stem cells in micro-environments optimized for screening and observing how they behaved when chemical changes were introduced.


It was found that two specific proteins within stem cells, Oct4 and Sox2, can be used to track the four major early cell fate types that stem cells can turn into, allowing four screens to be performed at once.


"One of the most frustrating challenges is that we have different research protocols for different cell types. But as it turns out, very often those protocols don't work across many different cell lines," Nazareth said.


The work also provides a way to study differences across cell lines that can be used to predict certain genetic information, such as abnormal chromosomes. What's more, these predictions can be done in a fraction of the time compared to other existing techniques, and for a substantially lower cost compared to other testing and screening methods.


"We anticipate this technology will underpin new strategies to identify cell fate control molecules, or even drugs, for a number of different stem cell types," Zandstra said.


As a drug screening technology "it's a dramatic improvement over its predecessors," said Nazareth. He notes that in some cases, the new technology can drop testing time from up to a month to a mere two days.


Professor Peter Zandstra was awarded the 2013 Till & McCulloch Award in recognition of this contribution to global stem cell research.


###

About IBBME:


The Institute of Biomaterials & Biomedical Engineering (IBBME) is an interdisciplinary unit allowing a remarkable degree of integration and collaboration across three Faculties at the University of Toronto: Applied Science & Engineering, Dentistry and Medicine. The Institute pursues research in four areas: neural, sensory systems and rehabilitation engineering; biomaterials, tissue engineering and regenerative medicine; molecular imaging and biomedical nanotechnology; and, medical devices and clinical technologies.




[ Back to EurekAlert! ]

[


| E-mail


Share Share

]

 


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.




Predicting the fate of stem cells


[ Back to EurekAlert! ]

PUBLIC RELEASE DATE:

22-Oct-2013



[


| E-mail

]


Share Share

Contact: Erin Vollick
Comm.ibbme@utoronto.ca
416-946-8019
University of Toronto



Technique has potential use in regenerative medicine and drug development



University of Toronto researchers have developed a method that can rapidly screen human stem cells and better control what they will turn into. The technology could have potential use in regenerative medicine and drug development. Findings are published in this week's issue of the journal Nature Methods.


"The work allows for a better understanding of how to turn stem cells into clinically useful cell types more efficiently," according to Emanuel Nazareth, a PhD student at the Institute of Biomaterials & Biomedical Engineering (IBBME) at the University of Toronto. The research comes out of the lab of Professor Peter Zandstra, Canada Research Chair in Bioengineering at U of T.


The researchers used human pluripotent stem cells (hPSC), cells which have the potential to differentiate and eventually become any type of cell in the body. But the key to getting stem cells to grow into specific types of cells, such as skin cells or heart tissue, is to grow them in the right environment in culture, and there have been challenges in getting those environments (which vary for different types of stem cells) just right, Nazareth said.


The researchers developed a high-throughput platform, which uses robotics and automation to test many compounds or drugs at once, with controllable environments to screen hPSCs in. With it, they can control the size of the stem cell colony, the density of cells, and other parameters in order to better study characteristics of the cells as they differentiate or turn into other cell types. Studies were done using stem cells in micro-environments optimized for screening and observing how they behaved when chemical changes were introduced.


It was found that two specific proteins within stem cells, Oct4 and Sox2, can be used to track the four major early cell fate types that stem cells can turn into, allowing four screens to be performed at once.


"One of the most frustrating challenges is that we have different research protocols for different cell types. But as it turns out, very often those protocols don't work across many different cell lines," Nazareth said.


The work also provides a way to study differences across cell lines that can be used to predict certain genetic information, such as abnormal chromosomes. What's more, these predictions can be done in a fraction of the time compared to other existing techniques, and for a substantially lower cost compared to other testing and screening methods.


"We anticipate this technology will underpin new strategies to identify cell fate control molecules, or even drugs, for a number of different stem cell types," Zandstra said.


As a drug screening technology "it's a dramatic improvement over its predecessors," said Nazareth. He notes that in some cases, the new technology can drop testing time from up to a month to a mere two days.


Professor Peter Zandstra was awarded the 2013 Till & McCulloch Award in recognition of this contribution to global stem cell research.


###

About IBBME:


The Institute of Biomaterials & Biomedical Engineering (IBBME) is an interdisciplinary unit allowing a remarkable degree of integration and collaboration across three Faculties at the University of Toronto: Applied Science & Engineering, Dentistry and Medicine. The Institute pursues research in four areas: neural, sensory systems and rehabilitation engineering; biomaterials, tissue engineering and regenerative medicine; molecular imaging and biomedical nanotechnology; and, medical devices and clinical technologies.




[ Back to EurekAlert! ]

[


| E-mail


Share Share

]

 


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.




Source: http://www.eurekalert.org/pub_releases/2013-10/uot-ptf102213.php
Related Topics: Avril Lavigne   Lake Natron   Sleepy Hollow   Daft Punk   EverQuest Next  

FDA can't find cause of pet poison, seeks help


LOS ANGELES (AP) — All that's left of Doodles are his ashes, a clay impression of his paw and a whole lot of questions owner Patricia Cassidy has about his mysterious death.

Doodles is believed to be one of 580 dogs in the U.S. that have died in the past six years from eating pet jerky from China. Baffled by the cause and seeing another surge in illnesses, the Food and Drug Administration reached out to owners and veterinarians Tuesday to help it find the poison behind the sickening of at least 3,600 dogs and 10 cats since 2007.

Within hours of eating the suspect jerky, pets lost their appetite, became lethargic, vomited and had diarrhea and other symptoms. The strips made of chicken, duck, sweet potatoes or dried fruit were sold under a variety of brand names.

There was a decrease in 2007 after some products were voluntarily removed from the market, but the FDA said it didn't want to conduct a recall without a definitive cause. Those products included Milo's Kitchen Chicken Jerky Treats and Chicken Grillers, made by Del Monte, and Waggin' Train and Canyon Creek Ranch dog treats, made by Nestle Purina.

But in the years since, the FDA has gotten complaints from pet owners and veterinarians who have seen repeated cases of kidney failure, gastrointestinal bleeding, and a rare kidney disorder, the FDA said.

The FDA's Center for Veterinary Medicine has run more than 1,200 tests, visited pet treat manufacturing plants in China and worked with researchers, state labs and foreign governments but hasn't determined the exact cause of the illness.

Testing is complicated because the poison may have come from the manufacturing plant, shipping, transportation or anywhere along the way. Scientists have to know what they're looking for to test for it.

"I grew up watching 'Quincy' and 'CSI' and they have given us this look at forensics — you put samples in and answers come out the other end," said Dr. Tina Wismer, medical director of the Animal Poison Control Center of the American Society for the Prevention of Cruelty to Animals. It doesn't work that way."

That's little consolation to Cassidy in Chattanooga, Tenn. Doodles died Sept. 9 at the age of 6. In just three months, he turned from a vibrant 16-pound shih tzu into a frail, 6-pounder who couldn't eat or drink and had so little left in him he could only vomit yellow bile.

"He was such a loving little guy and so cute. Every day my daughter will say, 'Mom, I don't know when the holes in our hearts will be repaired.'"

Cassidy promised Doodles she would wage war as long as it took to get the products off store shelves or, at the very least, labeled so people know it might be deadly.

The jerky mystery is the worst case of tainted pet food from China since 2007 when there was a nationwide recall of food made by Menu Foods and 1,950 cats and 2,200 dogs died. Kidney failure caused all of those pet deaths and the poison was found to be tainted melamine from plastic packaging in the wheat gluten. About 150 brands of dog and cat food were recalled and included some of the biggest names in pet food.

A federal grand jury indicted two Chinese nationals and the businesses they operate, as well as the U.S, company ChemNutra Inc. and its CEO for their roles in importing the poisonous products. A class-action lawsuit awarded more than $12.4 million in compensation to pet owners whose pets died from the poisoned food.

Veterinarians can only tell pet owners they don't know what's causing their animals to get sick and that's hard to do, said Dr. Karl Jandrey, an emergency and critical care vet at the Veterinary Medical Teaching Hospital at the University of California, Davis. They have treated several dogs for what they believe was poisoning from the treats, but no patient has died, he said.

Dexter, a 3-year-old, 19-pound miniature schnauzer also survived, but it cost owner Rich Phillips of North Richland Hills, Texas, about $1,200, he said.

In April, Dexter started throwing up and couldn't stop. He spent the night at an emergency clinic and the next day at the vet's. Test after test was inconclusive. The dog was given an IV and anti-nausea medicine and sent home. That's when Phillips saw the package of chicken jerky treats and knew that was the cause. "We were lucky we caught him quick," Phillips said. Dexter had only had about two of the treats and has been fine ever since that night.

No one knows how many treats a pet has to eat before it starts getting sick, said Dr Amy Bowman, regional medical director for Banfield Pet Hospital in Reston, Va.

"Some say it's a single serving, some say the whole bag," she said. Her advice is to avoid jerky treats if the label says it comes from China. There are all kinds of healthy treat substitutes, including apples, uncooked green beans and carrots, she added.

A lot of pet owners transfer food and treats into other containers at home to keep pets and pests out, but Wismer suggested keeping labels with lot numbers and manufacturers.

Imported pet food is inspected when it arrives in the United States but only randomly and to check for things like mold, Wismer said.

Dr. Barry Kellogg, senior adviser to the Humane Society Veterinary Medical Association, called for increased testing and stricter guidelines on labeling of imports. If only part of a product is from China and it is put together here, labels don't have to say made in China, he said.

___

Writer Mary Clare Jalonick reported on this story from Washington.

___

Online:

Food and Drug Administration statement http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm371413.htm

Source: http://news.yahoo.com/fda-cant-cause-pet-poison-seeks-help-051451393.html
Tags: columbus day   Dusty Baker   alyssa milano  

Japan's Abe: to use extra tax revenue, not new debt, for stimulus spending


TOKYO (Reuters) - Japanese Prime Minister Shinzo Abe said on Thursday he plans to use higher-than-expected tax revenue to fund economic stimulus spending rather than relying on issuing new debt.


Abe was speaking in the upper house budget committee.


The government will announce in early December details of a 5 trillion yen ($51 billion) economic stimulus package meant to offset the drag from an increase in the sales tax next April. ($1 = 97.2900 Japanese yen)


(Reporting by Stanley White; Editing by Chang-Ran Kim)

Source: http://news.yahoo.com/japans-abe-extra-tax-revenue-not-debt-stimulus-014549246--business.html
Related Topics: Cricinfo   glee   john lennon   labor day   auburn football  

Lindsay Lohan Sued for Summer Porsche Wreck

She may be out of rehab and getting herself on the right track, but Lindsay Lohan's past is coming back to haunt her.


Stemming from an accident back in early June when her Porsche hit a semi, a lawsuit from the other driver has just been filed.


According to TMZ, truck driver James Johnson claims he suffered injuries and great physical, mental, and nervous pain from the accident.


At the scene, police found pills in her purse and a water bottle that smelled of alcohol. Meanwhile, the 27-year-old actress is still working on recovery, receiving court-ordered therapy.


Source: http://celebrity-gossip.net/lindsay-lohan/lindsay-lohan-sued-summer-porsche-wreck-948515
Similar Articles: silk road   Mike Wayans   LC Greenwood   Mr Cee   david cassidy  

Quick turn: Reversed call leads to 8-1 Boston win

St. Louis Cardinals manager Mike Matheny argues a call during the first inning of Game 1 of baseball's World Series against the Boston Red Sox Wednesday, Oct. 23, 2013, in Boston. (AP Photo/Elise Amendola)







St. Louis Cardinals manager Mike Matheny argues a call during the first inning of Game 1 of baseball's World Series against the Boston Red Sox Wednesday, Oct. 23, 2013, in Boston. (AP Photo/Elise Amendola)







St. Louis Cardinals manager Mike Matheny argues a call with umpire John Hirschbeck during the first inning of Game 1 of baseball's World Series against the Boston Red Sox Wednesday, Oct. 23, 2013, in Boston. (AP Photo/Matt Slocum)







St. Louis Cardinals manager Mike Matheny argues a call during the first inning of Game 1 of baseball's World Series against the Boston Red Sox Wednesday, Oct. 23, 2013, in Boston. (AP Photo/Charlie Riedel)







Boston Red Sox manager John Farrell argues a call with umpire Dana DeMuth during the first inning of Game 1 of baseball's World Series against the St. Louis Cardinals Wednesday, Oct. 23, 2013, in Boston. (AP Photo/David J. Phillip)







St. Louis Cardinals' Pete Kozma can't handle a throw as Boston Red Sox's Dustin Pedroia slides into second during the first inning of Game 1 of baseball's World Series Wednesday, Oct. 23, 2013, in Boston. (AP Photo/Charlie Riedel)







(AP) — No need for instant replay. The umpires overturned this blown call on their own.

After Dustin Pedroia was called out on a phantom force play in the first inning of the World Series opener, second base umpire Dana DeMuth was reversed by the other five members of his crew.

Three pitches later, Mike Napoli lined a cutter to the gap in left-center field for a go-ahead three-run double, and the Boston Red Sox coasted to an 8-1 rout over the St. Louis Cardinals on Wednesday night.

Nine years after they reversed the Curse, the Red Sox succeeded in reversing a key Series call.

"You rarely see that," Napoli said before adding, "especially on a stage like this."

Jacoby Ellsbury had walked leading off the first, and Pedroia had singled with one out. David Ortiz followed with a slow bouncer to second baseman Matt Carpenter that had an outside chance of being turned into an inning-ending double play.

Carpenter made a routine 30-foot backhand flip to Pete Kozma in plenty of time for the out. But as the shortstop approached second base, the ball bounced off the edge of his glove's webbing and fell to the ground.

DeMuth called Pedroia out on a force, indicating the ball was dropped by Kozma while making the transfer to his throwing hand.

"It was just one of those plays. He gave me a good feed and I just missed it," Kozma said.

Red Sox manager John Farrell jogged out from the dugout out to argue.

"I think we're fully accepting of the neighborhood play, but my view is that it wasn't even that," he said. "There was really no entry into the glove with the ball."

All six umpires huddled near shortstop for 30 seconds to discuss the play as Farrell looked on from the infield grass.

"Typically they're probably going to stand pat with the decision that's made in the moment," Farrell said.

Kozma believed he established sufficient possession.

"I had enough," he said.

And then crew chief John Hirschbeck then walked toward the Cardinals dugout on the third-base side, motioning with his left hand for Cardinals manager Mike Matheny to come out. He told him that Pedroia was being called safe, and Matheny spent 1½ minutes arguing to no avail, repeatedly jabbing his right index finger in the air.

"That's not a play I've ever seen before," Matheny said. "And I'm pretty sure there were six umpires on the field that had never seen that play before either. It's a pretty tough time to debut that overruled call in the World Series. Now, I get that trying to get the right call. I get that. Tough one to swallow."

DeMuth admitted he got it wrong.

"I stayed with the foot too long. That's how I ended up getting in trouble," he said. "And when I was coming up, all I could see was a hand coming out and the ball on the ground. All right? So I was assuming."

When he saw his crewmates converging on him, DeMuth knew he had made a mistake.

"It's an awful feeling, yeah. Especially when I'm sure I have the right call," he said.

Hirschbeck said in the end it wasn't a difficult decision for the crew.

"'When I hear all five of us say we are 100 percent, then I say, 'OK, we need to change this.' It's as simple as that," he said.

Major League Baseball started using video review to assist umpires in 2008, but only to decide whether potential home runs went over fences or were fair balls.

Under rules changes likely to be approved for next season, video will be used for virtually every call other than balls and strikes. Managers would be allowed one challenge over the first six innings and two from the seventh inning on. Officials in New York City would make the final ruling.

Speaking softly in a corner of the cramped visitors' clubhouse, Kozma seemed like a player who felt he had let his team down.

"You saw what happened the rest of the night," he said. "If I catch that ball and turn that double play, it stays nothing-nothing."

Associated PressSource: http://hosted2.ap.org/APDEFAULT/347875155d53465d95cec892aeb06419/Article_2013-10-24-BBO-World-Series-Call-Reversed/id-d9686936af174067b6ba3f1ae92c7743
Related Topics: Maria de Villota   mlb   dexter   detroit lions   blue moon